418 related articles for article (PubMed ID: 29471853)
41. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
[TBL] [Abstract][Full Text] [Related]
42. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
43. Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells.
Cheng R; Liu YJ; Cui JW; Yang M; Liu XL; Li P; Wang Z; Zhu LZ; Lu SY; Zou L; Wu XQ; Li YX; Zhou Y; Fang ZY; Wei W
Oncotarget; 2017 May; 8(18):30252-30264. PubMed ID: 28415819
[TBL] [Abstract][Full Text] [Related]
44. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
[TBL] [Abstract][Full Text] [Related]
45. COX-2 silencing enhances tamoxifen antitumor activity in breast cancer in vivo and in vitro.
Du Y; Shi A; Han B; Li S; Wu D; Jia H; Zheng C; Ren L; Fan Z
Int J Oncol; 2014 Apr; 44(4):1385-93. PubMed ID: 24535190
[TBL] [Abstract][Full Text] [Related]
46. FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression.
Lv Q; Guan S; Zhu M; Huang H; Wu J; Dai X
Technol Cancer Res Treat; 2021; 20():15330338211004935. PubMed ID: 33783288
[TBL] [Abstract][Full Text] [Related]
47. Silencing of MicroRNA-21 confers the sensitivity to tamoxifen and fulvestrant by enhancing autophagic cell death through inhibition of the PI3K-AKT-mTOR pathway in breast cancer cells.
Yu X; Li R; Shi W; Jiang T; Wang Y; Li C; Qu X
Biomed Pharmacother; 2016 Feb; 77():37-44. PubMed ID: 26796263
[TBL] [Abstract][Full Text] [Related]
48. Oncogenic HBXIP enhances ZEB1 through Sp1 to accelerate breast cancer growth.
Jiang Y; Wang D; Ren H; Shi Y; Gao Y
Thorac Cancer; 2018 Dec; 9(12):1664-1670. PubMed ID: 30273966
[TBL] [Abstract][Full Text] [Related]
49. Downregulation of Choline Kinase-Alpha Enhances Autophagy in Tamoxifen-Resistant Breast Cancer Cells.
Kim HS; Tian L; Jung M; Choi SK; Sun Y; Kim H; Moon WK
PLoS One; 2015; 10(10):e0141110. PubMed ID: 26496360
[TBL] [Abstract][Full Text] [Related]
50. The oncoprotein HBXIP up-regulates FGF4 through activating transcriptional factor Sp1 to promote the migration of breast cancer cells.
Shi H; Li Y; Feng G; Li L; Fang R; Wang Z; Qu J; Ding P; Zhang X; Ye L
Biochem Biophys Res Commun; 2016 Feb; 471(1):89-94. PubMed ID: 26828265
[TBL] [Abstract][Full Text] [Related]
51. Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer.
Lee J; Jeong JH; Jung JH; Kim WW; Lee SJ; Park JY; Park JY; Kang SH; Kim EA; Park JH; Chae YS; Park HY
Oncology; 2019; 97(3):180-188. PubMed ID: 31330520
[TBL] [Abstract][Full Text] [Related]
52. The oncoprotein HBXIP upregulates Lin28B via activating TF II D to promote proliferation of breast cancer cells.
Liu Q; Bai X; Li H; Zhang Y; Zhao Y; Zhang X; Ye L
Int J Cancer; 2013 Sep; 133(6):1310-22. PubMed ID: 23494474
[TBL] [Abstract][Full Text] [Related]
53. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer.
Madhavan S; Gusev Y; Singh S; Riggins RB
J Exp Clin Cancer Res; 2015 May; 34(1):45. PubMed ID: 25971350
[TBL] [Abstract][Full Text] [Related]
54. Differential regulation of ErbB2 expression by cAMP-dependent protein kinase in tamoxifen-resistant breast cancer cells.
Yang JW; Kim MR; Kim HG; Kim SK; Jeong HG; Kang KW
Arch Pharm Res; 2008 Mar; 31(3):350-6. PubMed ID: 18409049
[TBL] [Abstract][Full Text] [Related]
55. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.
Selever J; Gu G; Lewis MT; Beyer A; Herynk MH; Covington KR; Tsimelzon A; Dontu G; Provost P; Di Pietro A; Boumendjel A; Albain K; Miele L; Weiss H; Barone I; Ando S; Fuqua SA
Clin Cancer Res; 2011 Oct; 17(20):6510-21. PubMed ID: 21878538
[TBL] [Abstract][Full Text] [Related]
56. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
57. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
[TBL] [Abstract][Full Text] [Related]
58. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.
Nagelkerke A; Sieuwerts AM; Bussink J; Sweep FC; Look MP; Foekens JA; Martens JW; Span PN
Endocr Relat Cancer; 2014 Feb; 21(1):101-12. PubMed ID: 24434718
[TBL] [Abstract][Full Text] [Related]
59. Identification of Sirtuin 3, a mitochondrial protein deacetylase, as a new contributor to tamoxifen resistance in breast cancer cells.
Zhang L; Ren X; Cheng Y; Huber-Keener K; Liu X; Zhang Y; Yuan YS; Yang JW; Liu CG; Yang JM
Biochem Pharmacol; 2013 Sep; 86(6):726-33. PubMed ID: 23856293
[TBL] [Abstract][Full Text] [Related]
60. iRGD-guided tamoxifen polymersomes inhibit estrogen receptor transcriptional activity and decrease the number of breast cancer cells with self-renewing capacity.
Diaz Bessone MI; Simón-Gracia L; Scodeller P; Ramirez MLA; Lago Huvelle MA; Soler-Illia GJAA; Simian M
J Nanobiotechnology; 2019 Dec; 17(1):120. PubMed ID: 31812165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
